{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:21:41Z","timestamp":1788200501381,"version":"build-2803163510"},"reference-count":31,"publisher":"Bentham Science Publishers Ltd.","issue":"2","funder":[{"DOI":"10.13039\/501100004305","name":"Shahroud University of Medical Sciences","doi-asserted-by":"publisher","award":["9667"],"award-info":[{"award-number":["9667"]}],"id":[{"id":"10.13039\/501100004305","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CAD"],"published-print":{"date-parts":[[2020,3,25]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>The catecholamines such as dopamine, norepinephrine, and epinephrine\nare neurotransmitters that regulate different physiological functions of the central nervous system.\nSome evidence suggests that the degeneration of dopamine neurons in the substantia nigra contributes\nto Parkinson\u2019s Disease (PD), which is a neurodegenerative disorder and it is responsible for the\nmajor symptoms of PD. It is suggested that replenishment of striatal dopamine through the oral\nadministration of the dopamine precursor, levodopa, can compensate for the lack of endogenously\nproduced dopamine. Some studies have shown competitive inhibition of dopamine receptor such as\nmethamphetamine, and other amphetamine-related derivatives, which block dopamine receptor activity\nto uptake dopamine.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>In this study, 3D structures of amphetamine, methamphetamine, cocaine, methylphenidate,\ncathinone, MDMA, and mephedrone were obtained from the PubChem database, which has\nreported some evidence about their inhibitory effect with dopamine receptor. Then, these structures\nwere provided for molecular docking analysis by Autodock Vina software. Eventually, the binding\nenergies between docked dopamine receptor and them were calculated and their interactions were\nprognosticated.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Our results indicated that all chemicals can interact with dopamine receptor molecule in\nthe active site of dopamine and the minimum binding energies belong to Cocaine and\nMethylphenidate with -7.9 Kcal\/mol and -7.2 Kcal\/mol, respectively.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>It might be concluded that amphetamine, methamphetamine, cocaine, methylphenidate,\ncathinone, MDMA, and mephedrone could act as potential inhibitors of DA receptor for dopamine\nuptake, which could cause degenerative disorders.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573409915666181204144411","type":"journal-article","created":{"date-parts":[[2018,12,4]],"date-time":"2018-12-04T12:09:55Z","timestamp":1543925395000},"page":"122-133","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Molecular Docking Studies of Methamphetamine and Amphetamine- Related Derivatives as an Inhibitor against Dopamine Receptor"],"prefix":"10.2174","volume":"16","author":[{"given":"Kobra","family":"Foroughi","sequence":"first","affiliation":[{"name":"Department of Medical Biotechnology, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Khaksari","sequence":"additional","affiliation":[{"name":"Addiction Research Center, Shahroud University of Medical Sciences, Shahroud, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asghar","family":"Shayannia","sequence":"additional","affiliation":[{"name":"Department of Medical Biotechnology, School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1046\/j.0022-202x.2001.00011.x","volume":"6","author":"Kobayashi K.","year":"2001","unstructured":"Kobayashi K.; Role of catecholamine signaling in brain and nervous system functions: new insights from mouse molecular genetic study. J Investig Dermatol Symp Proc 2001,6(1),115-121","journal-title":"J Investig Dermatol Symp Proc"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1124\/pr.56.3.1","volume":"56","author":"Eisenhofer G.","year":"2004","unstructured":"Eisenhofer G.; Kopin I.J.; Goldstein D.S.; Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol Rev 2004,56(3),331-349","journal-title":"Pharmacol Rev"},{"key":"ref=3","first-page":"Vol. 42, pp. 1-14","author":"Nagatsu T.","year":"1997","unstructured":"Nagatsu T.; Stj\u00e4rnet L.; Catecholamine Synthesis and Release. Advances in Pharmacology Goldstein, D.S.; Eisenhofer, G.; McCarty, R., Eds.; Academic Press1997,Vol. 42, pp. 1-14","journal-title":"Advances in Pharmacology"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.pbb.2007.10.014","volume":"90","author":"Phillips A.G.","year":"2008","unstructured":"Phillips A.G.; Vacca G.; Ahn S.; A top-down perspective on dopamine, motivation and memory. Pharmacol Biochem Behav 2008,90(2),236-249","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/j.1471-4159.1989.tb11788.x","volume":"53","author":"Menniti F.S.","year":"1989","unstructured":"Menniti F.S.; Diliberto E.J.; Newly synthesized dopamine as the precursor for norepinephrine synthesis in bovine adrenomedullary chromaffin cells. J Neurochem 1989,53(3),890-897","journal-title":"J Neurochem"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1212\/01.wnl.0000341769.50075.bb","volume":"72","author":"Driver J.A.","year":"2009","unstructured":"Driver J.A.; Logroscino G.; Gaziano J.M.; Kurth T.; Incidence and remaining lifetime risk of Parkinson disease in advanced age. Neurology 2009,72(5),432-438","journal-title":"Neurology"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1096\/fj.12-220418","volume":"27","author":"Michel P.P.","year":"2013","unstructured":"Michel P.P.; Toulorge D.; Guerreiro S.; Hirsch E.C.; Specific needs of dopamine neurons for stimulation in order to survive: implication for Parkinson disease. FASEB J 2013,27(9),3414-3423","journal-title":"FASEB J"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","volume":"39","author":"Dauer W.","year":"2003","unstructured":"Dauer W.; Przedborski S.; Parkinson\u2019s disease: mechanisms and models. Neuron 2003,39(6),889-909","journal-title":"Neuron"},{"key":"ref=9","first-page":"47","volume":"5","author":"Brisch R.","year":"2014","unstructured":"Brisch R.; Saniotis A.; Wolf R.; Bielau H.; Bernstein H-G.; Steiner J.; Bogerts B.; Braun K.; Jankowski Z.; Kumaratilake J.; Henneberg M.; Gos T.; The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front Psychiatry 2014,5(47),47","journal-title":"Front Psychiatry"},{"key":"ref=10","first-page":"63","author":"Rankin L.","year":"2010","unstructured":"Rankin L.;  M; A; Hazelwood; L; Free, R; B, Namkung; Y, Rex; E, Roof; Sibley, D 2010,63-87","journal-title":"M; A; Hazelwood; L; Free, R; B, Namkung; Y, Rex; E, Roof; Sibley, D"},{"key":"ref=11","first-page":"137","volume":"6","author":"Lei S.","year":"2014","unstructured":"Lei S.; Cross interaction of dopaminergic and adrenergic systems in neural modulation. Int J Physiol Pathophysiol Pharmacol 2014,6(3),137-142","journal-title":"Int J Physiol Pathophysiol Pharmacol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1074\/jbc.M805298200","volume":"284","author":"Goodwin J.S.","year":"2009","unstructured":"Goodwin J.S.; Larson G.A.; Swant J.; Sen N.; Javitch J.A.; Zahniser N.R.; De Felice L.J.; Khoshbouei H.; Amphetamine and methamphetamine differentially affect dopamine transporters in vitro and in vivo. J Biol Chem 2009,284(5),2978-2989","journal-title":"J Biol Chem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0006-8993(97)01281-X","volume":"782","author":"Bennett B.A.","year":"1998","unstructured":"Bennett B.A.; Hollingsworth C.K.; Martin R.S.; Harp J.J.; Methamphetamine-induced alterations in dopamine transporter function. Brain Res 1998,782(1-2),219-227","journal-title":"Brain Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/nn.2146","volume":"11","author":"Beuming T.","year":"2008","unstructured":"Beuming T.; Kniazeff J.; Bergmann M.L.; Shi L.; Gracia L.; Raniszewska K.; Newman A.H.; Javitch J.A.; Weinstein H.; Gether U.; Loland C.J.; The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci 2008,11(7),780-789","journal-title":"Nat Neurosci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"9, pp. 1-11","DOI":"10.2147\/AABC.S105289","author":"de Ruyck J.","year":"2016","unstructured":"de Ruyck J.; Brysbaert G.; Blossey R.; Lensink M.;  Molecular\ndocking as a popular tool in drug design, an in silico travel; 2016,9, pp. 1-11","journal-title":"Molecular\ndocking as a popular tool in drug design, an in silico travel;"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"D475","DOI":"10.1093\/nar\/gks1200","volume":"41","author":"Rose P.W.","year":"2013","unstructured":"Rose P.W.; Bi C.; Bluhm W.F.; Christie C.H.; Dimitropoulos D.; Dutta S.; Green R.K.; Goodsell D.S.; Prli\u0107 A.; Quesada M.; Quinn G.B.; Ramos A.G.; Westbrook J.D.; Young J.; Zardecki C.; Berman H.M.; Bourne P.E.; The RCSB Protein Data Bank: new resources for research and education. Nucleic Acids Res 2013,41(Database issue),D475-D482","journal-title":"Nucleic Acids Res"},{"key":"ref=17","first-page":"442","volume":"30","author":"DeLano W.L.","year":"2002","unstructured":"DeLano W.L.; The PyMOL molecular graphics system Proteins: Structure, Function and Bioinformatics. Fuzziness: Structural Disorder in Protein Complexes 2002,30,442-454","journal-title":"Fuzziness: Structural Disorder in Protein Complexes"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1021\/ci200227u","volume":"51","author":"Laskowski R.A.","year":"2011","unstructured":"Laskowski R.A.; Swindells M.B.; LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model 2011,51(10),2778-2786","journal-title":"J Chem Inf Model"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2174\/157340911795677602","volume":"7","author":"Meng X-Y.","year":"2011","unstructured":"Meng X-Y.; Zhang H-X.; Mezei M.; Cui M.; Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des 2011,7(2),146-157","journal-title":"Curr Comput Aided Drug Des"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.pbb.2006.03.007","volume":"83","author":"Claytor R.","year":"2006","unstructured":"Claytor R.; Lile J.A.; Nader M.A.; The effects of eticlopride and the selective D3-antagonist PNU 99194-A on food- and cocaine-maintained responding in rhesus monkeys. Pharmacol Biochem Behav 2006,83(3),456-464","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00213-007-0923-8","volume":"195","author":"Hall D.A.","year":"2008","unstructured":"Hall D.A.; Stanis J.J.; Marquez Avila H.; Gulley J.M.; A comparison of amphetamine- and methamphetamine-induced locomotor activity in rats: evidence for qualitative differences in behavior. Psychopharmacology (Berl) 2008,195(4),469-478","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/joim.12049","volume":"273","author":"Ares-Santos S.","year":"2013","unstructured":"Ares-Santos S.; Granado N.; Moratalla R.; The role of dopamine receptors in the neurotoxicity of methamphetamine. J Intern Med 2013,273(5),437-453","journal-title":"J Intern Med"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"8923","DOI":"10.1523\/JNEUROSCI.1033-13.2013","volume":"33","author":"Calipari E.S.","year":"2013","unstructured":"Calipari E.S.; Ferris M.J.; Amphetamine mechanisms and actions at the dopamine terminal revisited. J Neurosci 2013,33(21),8923-8925","journal-title":"J Neurosci"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1471-4159.2005.03199.x","volume":"94","author":"Chen R.","year":"2005","unstructured":"Chen R.; Han D.D.; Gu H.H.; A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate. J Neurochem 2005,94(2),352-359","journal-title":"J Neurochem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1038\/ncomms3720","volume":"4","author":"Calipari E.S.","year":"2013","unstructured":"Calipari E.S.; Ferris M.J.; Salahpour A.; Caron M.G.; Jones S.R.; Methylphenidate amplifies the potency and reinforcing effects of amphetamines by increasing dopamine transporter expression. Nat Commun 2013,4,2720-2720","journal-title":"Nat Commun"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1124\/jpet.108.141713","volume":"327","author":"Tilley M.R.","year":"2008","unstructured":"Tilley M.R.; Gu H.H.; The effects of methylphenidate on knockin mice with a methylphenidate-resistant dopamine transporter. J Pharmacol Exp Ther 2008,327(2),554-560","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"15057","DOI":"10.1021\/jp900963n","volume":"113","author":"Huang X.","year":"2009","unstructured":"Huang X.; Gu H.H.; Zhan C-G.; Mechanism for cocaine blocking the transport of dopamine: insights from molecular modeling and dynamics simulations. J Phys Chem B 2009,113(45),15057-15066","journal-title":"J Phys Chem B"},{"key":"ref=28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061245","volume":"8","author":"Navarro G.","year":"2013","unstructured":"Navarro G.; Moreno E.; Bonaventura J.; Brugarolas M.; Farr\u00e9 D.; Aguinaga D.; Mallol J.; Cort\u00e9s A.; Casad\u00f3 V.; Llu\u00eds C.; Ferre S.; Franco R.; Canela E.; McCormick P.J.; Cocaine Inhibits Dopamine D.; Cocaine inhibits dopamine D2 receptor signaling via sigma-1-D2 receptor heteromers. PLoS One 2013,8(4)","journal-title":"PLoS One"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.pnpbp.2007.12.033","volume":"32","author":"Feyissa A.M.","year":"2008","unstructured":"Feyissa A.M.; Kelly J.P.; A review of the neuropharmacological properties of khat. Prog Neuropsychopharmacol Biol Psychiatry 2008,32(5),1147-1166","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1476-5381.2012.02145.x","volume":"168","author":"Simmler L.D.","year":"2013","unstructured":"Simmler L.D.; Buser T.A.; Donzelli M.; Schramm Y.; Dieu L.H.; Huwyler J.; Chaboz S.; Hoener M.C.; Liechti M.E.; Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 2013,168(2),458-470","journal-title":"Br J Pharmacol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ejphar.2015.03.004","volume":"755","author":"Pifl C.","year":"2015","unstructured":"Pifl C.; Reither H.; Hornykiewicz O.; The profile of mephedrone on human monoamine transporters differs from 3,4-methylenedioxymethamphetamine primarily by lower potency at the vesicular monoamine transporter. Eur J Pharmacol 2015,755,119-126","journal-title":"Eur J Pharmacol"}],"container-title":["Current Computer-Aided Drug Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/168033","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T03:21:06Z","timestamp":1586834466000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/168033\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,25]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3,25]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573409915666181204144411","relation":{},"ISSN":["1573-4099"],"issn-type":[{"value":"1573-4099","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3,25]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-09-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}